Literature DB >> 27610012

Metabolic aspects of adult patients with nonalcoholic fatty liver disease.

Ludovico Abenavoli1, Natasa Milic1, Laura Di Renzo1, Tomislav Preveden1, Milica Medić-Stojanoska1, Antonino De Lorenzo1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a major cause of chronic liver disease and it encompasses a spectrum from simple steatosis to steatohepatitis, fibrosis, or cirrhosis. The mechanisms involved in the occurrence of NAFLD and its progression are probably due to a metabolic profile expressed within the context of a genetic predisposition and is associated with a higher energy intake. The metabolic syndrome (MS) is a cluster of metabolic alterations associated with an increased risk for the development of cardiovascular diseases and diabetes. NAFLD patients have more than one feature of the MS, and now they are considered the hepatic components of the MS. Several scientific advances in understanding the association between NAFLD and MS have identified insulin resistance (IR) as the key aspect in the pathophysiology of both diseases. In the multi parallel hits theory of NAFLD pathogenesis, IR was described to be central in the predisposition of hepatocytes to be susceptible to other multiple pathogenetic factors. The recent knowledge gained from these advances can be applied clinically in the prevention and management of NAFLD and its associated metabolic changes. The present review analyses the current literature and highlights the new evidence on the metabolic aspects in the adult patients with NAFLD.

Entities:  

Keywords:  Insulin resistance; Metabolic syndrome; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Obesity

Mesh:

Substances:

Year:  2016        PMID: 27610012      PMCID: PMC4988304          DOI: 10.3748/wjg.v22.i31.7006

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  96 in total

Review 1.  Association of recently described adipokines with liver histology in biopsy-proven non-alcoholic fatty liver disease: a systematic review.

Authors:  M Bekaert; X Verhelst; A Geerts; B Lapauw; P Calders
Journal:  Obes Rev       Date:  2015-11-24       Impact factor: 9.213

Review 2.  Nonalcoholic fatty liver disease.

Authors:  F Schaffner; H Thaler
Journal:  Prog Liver Dis       Date:  1986

Review 3.  What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome?

Authors:  Giovanni Tarantino; Carmine Finelli
Journal:  World J Gastroenterol       Date:  2013-06-14       Impact factor: 5.742

4.  Fatty acid metabolism is altered in non-alcoholic steatohepatitis independent of obesity.

Authors:  Paula Walle; Markus Takkunen; Ville Männistö; Maija Vaittinen; Maria Lankinen; Vesa Kärjä; Pirjo Käkelä; Jyrki Ågren; Mika Tiainen; Ursula Schwab; Johanna Kuusisto; Markku Laakso; Jussi Pihlajamäki
Journal:  Metabolism       Date:  2016-01-23       Impact factor: 8.694

5.  Hepatic fat loss in advanced nonalcoholic steatohepatitis: are alterations in serum adiponectin the cause?

Authors:  David van der Poorten; Caroline F Samer; Mehdi Ramezani-Moghadam; Sally Coulter; Marina Kacevska; Dennis Schrijnders; Lindsay E Wu; Duncan McLeod; Elisabetta Bugianesi; Mina Komuta; Tania Roskams; Christopher Liddle; Lionel Hebbard; Jacob George
Journal:  Hepatology       Date:  2013-01-18       Impact factor: 17.425

Review 6.  The role of leptin/adiponectin ratio in metabolic syndrome and diabetes.

Authors:  Patricio López-Jaramillo; Diego Gómez-Arbeláez; Jose López-López; Cristina López-López; Javier Martínez-Ortega; Andrea Gómez-Rodríguez; Stefany Triana-Cubillos
Journal:  Horm Mol Biol Clin Investig       Date:  2014-04

Review 7.  HDLs, diabetes, and metabolic syndrome.

Authors:  Peter Vollenweider; Arnold von Eckardstein; Christian Widmann
Journal:  Handb Exp Pharmacol       Date:  2015

Review 8.  Gut Microbiota of Nonalcoholic Fatty Liver Disease.

Authors:  Reham M Abdou; Lixin Zhu; Robert D Baker; Susan S Baker
Journal:  Dig Dis Sci       Date:  2016-02-22       Impact factor: 3.199

Review 9.  Nonalcoholic fatty liver disease as a multi-systemic disease.

Authors:  Hakan Fotbolcu; Elçin Zorlu
Journal:  World J Gastroenterol       Date:  2016-04-28       Impact factor: 5.742

10.  Association of Tumor Necrosis Factor-alpha Polymorphisms and Risk of Coronary Artery Disease in Patients With Non-alcoholic Fatty Liver Disease.

Authors:  Yuting Cheng; Baiquan An; Man Jiang; Yongning Xin; Shiying Xuan
Journal:  Hepat Mon       Date:  2015-03-31       Impact factor: 0.660

View more
  57 in total

1.  Is possible to detect nonalcoholic fatty liver disease by a new index including single nucleotide polymorphisms (SNPs)?

Authors:  Ludovico Abenavoli; Luigi Boccuto
Journal:  Ann Transl Med       Date:  2018-09

2.  Fatty liver as a risk factor for progression from metabolically healthy to metabolically abnormal in non-overweight individuals.

Authors:  Yoshitaka Hashimoto; Masahide Hamaguchi; Takuya Fukuda; Akihiro Ohbora; Takao Kojima; Michiaki Fukui
Journal:  Endocrine       Date:  2017-05-16       Impact factor: 3.633

3.  Association of fetuin B with markers of liver fibrosis in nonalcoholic fatty liver disease.

Authors:  Thomas Ebert; Nicolas Linder; Alexander Schaudinn; Harald Busse; Joachim Berger; Ralf Lichtinghagen; Volker Keim; Johannes Wiegand; Thomas Karlas
Journal:  Endocrine       Date:  2017-09-15       Impact factor: 3.633

4.  Polyphenols Treatment in Patients with Nonalcoholic Fatty Liver Disease.

Authors:  Ludovico Abenavoli; Natasa Milic; Francesco Luzza; Luigi Boccuto; Antonino De Lorenzo
Journal:  J Transl Int Med       Date:  2017-09-30

5.  Resistin Levels in Non-alcoholic Fatty Liver Disease Pathogenesis.

Authors:  Carmela Colica; Ludovico Abenavoli
Journal:  J Transl Int Med       Date:  2018-03-28

6.  Could phthalates exposure contribute to the development of metabolic syndrome and liver disease in humans?

Authors:  Nataša Milošević; Maja Milanović; Jan Sudji; Dragana Bosić Živanović; Stefan Stojanoski; Bojan Vuković; Nataša Milić; Milica Medić Stojanoska
Journal:  Environ Sci Pollut Res Int       Date:  2019-12-06       Impact factor: 4.223

7.  Serum Adropin Levels Are Reduced in Adult Patients with Nonalcoholic Fatty Liver Disease.

Authors:  Orkide Kutlu; Özgür Altun; Okan Dikker; Şerife Aktaş; Neslihan Özsoy; Yücel Arman; Eylem Özgün Çil; Mustafa Özcan; Şengül Aydın Yoldemir; Murat Akarsu; İlkim Deniz Toprak; Kerem Kırna; Yasin Kutlu; Zeki Toprak; Hasan Eruzun; Tufan Tükek
Journal:  Med Princ Pract       Date:  2019-04-16       Impact factor: 1.927

8.  The Effect of Moderate Weight Loss on a Non-Invasive Biomarker of Liver Fibrosis: A Randomised Controlled Trial.

Authors:  Dimitrios A Koutoukidis; Susan A Jebb; Paul Aveyard; Nerys M Astbury
Journal:  Obes Facts       Date:  2020-03-20       Impact factor: 3.942

9.  Is endocan a novel potential biomarker of liver steatosis and fibrosis?

Authors:  Aleksandra Klisić; Nebojša Kavarić; Ludovico Abenavoli; Verica Stanišić; Vesna Spasojević-Kalimanovska; Jelena Kotur-Stevuljević; Ana Ninić
Journal:  J Med Biochem       Date:  2020-09-02       Impact factor: 3.402

10.  Metformin in Combination with Malvidin Prevents Progression of Non-Alcoholic Fatty Liver Disease via Improving Lipid and Glucose Metabolisms, and Inhibiting Inflammation in Type 2 Diabetes Rats.

Authors:  Wenlan Zou; Chen Zhang; Xuefang Gu; Xiaohong Li; Huiming Zhu
Journal:  Drug Des Devel Ther       Date:  2021-06-17       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.